N-(7,21-Dihydroxy-6,20-dimethyl-2,5,8,15,19,22-hexaoxo-17-propan-2-yl-18-oxa-1,4,7,13,14,21,27-heptazatricyclo[21.4.0.09,14]heptacosan-16-yl)-2-hydroxy-2-[2-hydroxy-6-methyl-5-(2-methylbutyl)oxan-2-yl]propanamide | 125228-51-5

• 物质功能分类: 生物化工 - 抑制剂
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: N-(7,21-Dihydroxy-6,20-dimethyl-2,5,8,15,19,22-hexaoxo-17-propan-2-yl-18-oxa-1,4,7,13,14,21,27-heptazatricyclo[21.4.0.09,14]heptacosan-16-yl)-2-hydroxy-2-[2-hydroxy-6-methyl-5-(2-methylbutyl)oxan-2-yl]propanamide
• CAS: 125228-51-5
• 化学式: C₃₈H₆₄N₈O₁₃
• 分子量: 841.0
• InChiKey: ZJZOPNINWIGNQW-UHFFFAOYSA-N

物化性质

• 密度：
  1.37±0.1 g/cm3(Predicted)
• 溶解度：
  DMF：可溶； DMSO：可溶；乙醇：可溶

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  59
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  280
• 氢给体数：
  8
• 氢受体数：
  15

制备方法与用途

L 156602 是一种 C5a 受体拮抗剂，能够抑制迟发型超敏反应的传出阶段。

文献信息

• Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
  申请人：Lichter Jay

  公开号：US10092580B2

  公开（公告）日：2018-10-09

  Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

  本文公开了用于治疗耳部疾病的组合物和方法，通过将这些组合物和成分直接施用到或通过灌注到目标虹膜结构，对患有耳部疾病的人局部施用调节耳部结构的组合物。
• CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
  申请人：Otonomy, Inc.

  公开号：EP2306975A2

  公开（公告）日：2011-04-13
• [EN] COMPLEMENT DEPLETING COMPOUNDS AND METHODS OF TREATING CANCER COMPRISING MONOCLONAL ANTIBODY THERAPY AND SAID COMPLEMENT DEPLETING COMPOUNDS<br/>[FR] COMPOSÉS D'APPAUVRISSEMENT DE COMPLÉMENT ET PROCÉDÉS DE TRAITEMENT DU CANCER COMPORTANT UNE THÉRAPIE AUX ANTICORPS MONOCLONAUX ET LESDITS COMPOSÉS D'APPAUVRISSEMENT DE COMPLÉMENT
  申请人：INCODE BIOPHARMACEUTICS INC

  公开号：WO2009149306A2

  公开（公告）日：2009-12-10

  Disclosed herein are methods and compositions for increasing the efficacy of monoclonal antibody therapies without inducing inflammation and/or agonizing the growth of a neoplastic cell. In some embodiments, the methods and compositions disclosed herein comprise co-administering an antibody and a complement modulating agent.
• [EN] CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS<br/>[FR] COMPOSITIONS À LIBÉRATION CONTRÔLÉE MODULANT LA STRUCTURE OTIQUE ET MODULANT LE SYSTÈME IMMUNITAIRE NATUREL ET PROCÉDÉS DE TRAITEMENT DE TROUBLES OTIQUES
  申请人：OTONOMY INC

  公开号：WO2010011605A2

  公开（公告）日：2010-01-28

  Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
• [EN] METHOD AND COMPOSITION FOR MODULATING THE IMMUNE SYSTEM AND VARIOUS INFLAMMATORY CONDITIONS COMPRISING COMPLEMENT DEPLETORS<br/>[FR] PROCÉDÉ ET COMPOSITION DESTINÉS À MODULER LE SYSTÈME IMMUNITAIRE ET DIVERSES AFFECTIONS INFLAMMATOIRES COMPRENANT DES AGENTS APPAUVRISSANT LE COMPLÉMENT
  申请人：INCODE BIOPHARMACEUTICS INC

  公开号：WO2010056399A1

  公开（公告）日：2010-05-20

  Disclosed herein are methods and compositions for modifying an immune system or treating an inflammatory disorder. In some embodiments, the methods and compositions disclosed herein comprise a complement modulating agent. In some embodiments, the methods and compositions further comprise a mAB.